Patent foramen ovale (PFO) is a relatively common congenital condition which has been implicated in cryptogenic stroke as a result of paradoxical thromboembolism by right-to-left shunting. Many studies have demonstrated that transcatheter PFO closure significantly reduced the incidence of recurrent strokes in a small group of high-risk patients with PFO and atrial septal aneurysm compared with antithrombotic drugs. Two-dimensional transoesophageal echocardiography (2D TEE) has become the election technique for guiding patent foramen ovale closure. Real-time Three-dimensional transoesophageal echocardiography (3D TEE) may be potentially superior to 2D TEE in the accurate assessment of the morphology and efficacy of transcatheter closure devices because of a better spacial orientation.
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Case report
We report the case of a 64-year-old man presenting with recurrent cryptogenic strokes. A two-dimensional transoesophageal echocardiography (2D TEE) was performed and a patent foramen ovale (PFO) with a giant atrial septal aneurysm was diagnosed. The patient was referred to our institution for percutaneous closure of the patent foramen ovale. An Amplatzer PFO occlusion system (ASO, AGA Medical, Golden Valley, MN, USA) was placed, guiding by fluoroscopy and (2D and real-time 3D) TEE. Real-time 3D TEE was performed using a Philips IE33 (Andover, MA, USA) ultrasound system with the X7-2t TEE transducer. Prior to the catheterization procedure, the PFO and its adjacent structures were identified utilizing a combination of 2D and 3D TEE. Careful attention was given to define the PFO and its relation to the superior and inferior vena cava inflow (superior-posterior and inferior-posterior aspects of the interatrial septum), the atrioventricular valves (inferior-anterior), the right pulmonary vein, and the retroaortic region (superior-anterior). Initially, the atrial septal size was measured using 2D TEE and the PFO stretch diameter in the long-axis was 5-10 mm ( Figure 1A ) unlike 3D TEE, that estimated the PFO stretch in 20 mm ( Figure 1B) . Then, the PFO was too measured using a semicompliant balloon; NuMed sizing balloon (NuMed, Hopkinton, NY, USA), filled with a diluted contrast agent over a 260 cm, 0.035 in. Amplatzer superstiff wire (Cook, Bloomington, IN, USA) that confirmed the PFO size estimated by 3DTEE. So, a 25-mm ASO device was chosen to match the PFO stretch diameter.
The device delivery system was advanced through a haemostatic valve sheath from the right common femoral vein through a transseptal sheath (Figures 2A and 3A and B) . Under fluoroscopic guidance, the ASO device was advanced through the delivery sheath into the left atrium. The left atrial disc was then deployed in the left atrium ( Figure 2B) . Alignment of the left atrial disc and deployment of the right atrial disc were performed under 3D TEE guidance ( Figures 2C and 3C) . Finally, device release was performed under fluoroscopic and real-time 3D TEE guidance without any complications ( Figure 2D and 3D) .
Discussion
Real-time two-dimensional transoesophageal echocardiography has traditionally been the method of choice for guiding transcatheter PFO closure.
As of September 2007, a new 3D TEE probe capable of live/real-time 3D imaging became commercially available for clinical practice. This electronically steered transducer permits conventional multiplane 2D TEE image acquisition; but also offers live 3D, 3D zoom, full volume 3D, and 3D colour Doppler imaging, utilizing the matrix array technology employed in its 3D TTE predecessor.
1,2 Potentially improved visualization, and therefore, better understanding of the intricate anatomic details of atrial septal defects and devices, 3 may improve the results of device closure. Thus, three-dimensional echocardiography may provide important information in several aspects. First, 3D TEE view depicts the anatomy of the atrial septal more clearly and shows in depth perception and resolution of adjacent structures, Secondly, 3D echocardiography will aid in pre-selection of patients for atrial septal defect device closure. Thirdly, such imaging may help in appropriate selection of the type and size of the atrial septal defect occluder device. 4 Fourthly, 3D echocardiography may provide unique imaging planes and projections to better comprehend successful device placement. Fifthly, 3D echocardiography will enhance our understanding of the atrial septal defects, and devices that will improve our understanding of standard 2D studies for planning and performing percutaneous device closure. For all these issues, 3D TEE visualization of these devices may be potentially superior to 2D TEE in the assessment of device deployment, malposition and relation to adjacent strucutures like the valve and the aortic root. 
